MedTrace Logo

Artificial Intelligence for the Prioritization of Genetic Background in Brugada Syndrome

NCT06376552 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-04-19

No results posted yet for this study

Summary

Brugada Syndrome (BS) is an inherited heart condition that can cause sudden cardiac arrest in young individuals. It's diagnosed through specific changes seen on an electrocardiogram (ECG). Currently, the only treatment option is a cardioverter defibrillator (ICD). Despite advances, much about BS remains unclear, including its genetic basis. This study aims to use advanced genetic sequencing and artificial intelligence to uncover new genetic factors contributing to BS. By understanding these factors better, we hope to improve risk assessment and treatment for affected individuals.

Conditions

  • Brugada Syndrome

Sponsors & Collaborators

  • IRCCS San Raffaele

    lead OTHER

Principal Investigators

  • Chiara Di Resta, PhD · IRCCS San Raffaele Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-19
Primary Completion
2022-06-06
Completion
2022-06-06

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06376552 on ClinicalTrials.gov